{
    "clinical_study": {
        "@rank": "68677", 
        "arm_group": [
            {
                "arm_group_label": "Acarbose/Metformin FDC", 
                "arm_group_type": "Experimental", 
                "description": "Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Acarbose/Metformin FDC; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose/Metformin FDC (containing 50 mg Acarbose and 500 mg Metformin)"
            }, 
            {
                "arm_group_label": "Acarbose+Metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without loose combination of Acarbose and Metformin; Day 1: oral sucrose load plus single dose of 1 tablet each of a loose combination of Acarbose 50 mg and Metformin 500 mg"
            }, 
            {
                "arm_group_label": "Acarbose", 
                "arm_group_type": "Active Comparator", 
                "description": "Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose 50 mg"
            }, 
            {
                "arm_group_label": "Metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Metformin 500 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "To establish the bioequivalence between Acarbose / Metformin FDC (50mg / 500mg) and loose\n      combination of Acarbose (Glucobay) (50mg) and Metformin (Glucophage) (500mg)."
        }, 
        "brief_title": "Bioequivalence Study for Acarbose / Metformin FDC", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus, Type II", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body Mass Index (BMI): 18 to 28 kg/m2 (inclusive)\n\n          -  Results of Glycosylated Hemoglobin A1c (HbA1c) value are within the normal range\n             (4.3-5.6%, inclusive)\n\n          -  Results of the 75 g oral glucose tolerance test (OGTT) during screening show:\n\n               -  Blood glucose before OGTT <110 mg/dL.\n\n               -  Blood glucose 1 hour after glucose loading <180 mg/dL\n\n               -  Blood glucose 2 hours after glucose loading <140 mg/dL\n\n        Exclusion Criteria:\n\n          -  A history of relevant diseases of internal organs (diabetes mellitus, Ileus,\n             Ileus-like symptoms, diseases that may significantly jeopardize body systems\n\n          -  Febrile illness within 1 week before drug administration\n\n          -  Family history of diabetes (within the second degree of relationship)\n\n          -  Known drug hypersensitivity or idiosyncrasy\n\n          -  Known severe allergies, non-allergic drug reactions, or multiple drug allergies\n\n          -  Habitual medication including Chinese herbal drugs\n\n          -  Intake of any drugs within 2 weeks of drug administration of period 1\n\n          -  Regular daily consumption of more than 1 L of usual beer or the equivalent quantity\n             of approximately 40 g of alcohol in another form\n\n          -  Donation of more than 150 mL of blood within 4 weeks before the screening examination\n\n          -  Participation in another clinical trial within 4 weeks before the screening\n             examination"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728740", 
            "org_study_id": "15420"
        }, 
        "intervention": [
            {
                "arm_group_label": "Acarbose/Metformin FDC", 
                "description": "Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose", 
                "intervention_name": "Acarbose/Metformin FDC (BAY81-9783)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Acarbose+Metformin", 
                    "Acarbose"
                ], 
                "description": "Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose", 
                "intervention_name": "Acarbose (Glucobay, BAYG5421)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Acarbose+Metformin", 
                    "Metformin"
                ], 
                "description": "Metformin 500mg, oral, single dose", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Acarbose"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bioequivalence", 
            "Acarbose", 
            "Metformin", 
            "FDC"
        ], 
        "lastchanged_date": "December 18, 2012", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomized, Non-blinded Crossover Study to Establish the Bioequivalence Between Fixed Dose Combination (FDC) and Loose Combination of Acarbose and Metformin and to Investigate the Potential for a Drug-drug Interaction Following Single Oral Dosing in Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Ratio of postprandial maximum concentration (Cmax) of plasma glucose following sucrose load with (Day 1) and without acarbose (Day 0)", 
                "safety_issue": "No", 
                "time_frame": "within 4 hours after sucrose load"
            }, 
            {
                "measure": "Ratio of postprandial Area Under the Curve (AUC(0 4)) of plasma glucose following sucrose load with (Day 1) and without acarbose (Day 0)", 
                "safety_issue": "No", 
                "time_frame": "within 4 hours after sucrose load"
            }, 
            {
                "measure": "Cmax of metformin", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours after dosing"
            }, 
            {
                "measure": "AUC(0-tn) of metformin", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728740"
        }, 
        "responsible_party": {
            "name_title": "Head of Clinical Sciences", 
            "organization": "Bayer Healthcare AG"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}